A phase II/III study of ANAVEX 2-73 and ANAVEX PLUS in patients with mild to moderate Alzheimer's disease
Phase of Trial: Phase II/III
Latest Information Update: 07 Feb 2018
At a glance
- Drugs ANAVEX 2-73 (Primary) ; ANAVEX-2-73/donepezil (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 07 Feb 2018 According to an Anavex Life Sciences media release, the company plans to submit an IND to the US FDA within the first quarter of 2018 for this study.
- 05 Sep 2017 According to an Anavex Life Sciences media release, the company expects to initiate this study in 2017.
- 20 Feb 2015 New trial record